Oncocross Co., Ltd. (KOSDAQ:382150)

South Korea flag South Korea · Delayed Price · Currency is KRW
12,790
-1,080 (-7.79%)
At close: Dec 5, 2025
Market Cap 153.71B
Revenue (ttm) 884.68M
Net Income (ttm) -8.33B
Shares Out 12.02M
EPS (ttm) -717.10
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 598,673
Average Volume 1,378,567
Open 13,620
Previous Close 13,870
Day's Range 12,750 - 13,620
52-Week Range 6,260 - 16,700
Beta n/a
RSI 58.76
Earnings Date Nov 10, 2025

About Oncocross

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular D... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 382150
Full Company Profile

Financial Performance

In 2024, Oncocross's revenue was 1.07 billion, an increase of 1071.49% compared to the previous year's 91.52 million. Losses were -6.48 billion, 53.8% more than in 2023.

Financial Statements

News

There is no news available yet.